deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT07278479

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Sponsor: Molecular Partners AG

Conditions Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) Gastroenteropancreatic NEC (GEP NEC) Large Cell Neuroendocrine Carcinoma Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC) NEC of the Bladder Other DLL3 Expressing epNEC Small Cell Lung Cancer (SCLC)
Interventions [203Pb]Pb-MP0712 [212Pb]Pb-MP0712
Updated 2 times since 2026 Last updated: Jan 8, 2026 Started: Jan 31, 2026 Primary completion: Sep 30, 2028 Completion: Sep 30, 2032
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07278479, this PHASE1/PHASE2 trial focuses on Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) and Gastroenteropancreatic NEC (GEP NEC) and remains actively recruiting participants. Sponsored by Molecular Partners AG, it has been updated 2 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2026 – present · 7 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1/PHASE2

    Status: Not Yet Recruiting → Recruiting

  2. Jan 2026 — Feb 2026 [monthly]

    Not Yet Recruiting PHASE1/PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Molecular Partners AG
  • Orano Med LLC
Data source: Molecular Partners AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations